Search for European Projects

5 European Projects Found

Searched on 125080 European Projects

 ONGOING 
IMMUNOSABR is geared towards opening up a new paradigm in treating metastatic cancer by obtaining clinical proof of concept for a novel bi-modal curative treatment strategy. High precision stereotactic ablative radiotherapy (SABR) is combined with immunotherapy to form a powerful synergistic anti-tumour strategy. The approach relies on the direct cytotoxic effect of SABR, the abscopal effect of ra ...
Read Project

 17

 FINISHED 

Advanced T-cell Engineered for Cancer Therapy (ATECT)

Start date: Dec 1, 2013, End date: Nov 30, 2018,

"T-cell engineering strategies for Cancer therapy, either Chimeric Antigen Receptors (CARs) or TCR transfer holds promise to revolutionize cancer treatment. There are, however, considerable barriers to be overcome to take this form of therapy to a format that can benefit all EU citizens with a wide range of common cancers. The aim of this consortium is to exploit advances in T-cell engineering to ...
Read Project

 6

 FINISHED 
EURenOmics will integrate several established consortia devoted to rare kidney diseases with eminent need and potential for diagnostic and therapeutic progress (i.e. steroid resistant nephrotic syndrome, membranous nephropathy, tubulopathies, complement disorders such a haemolytic uraemic syndrome, and congenital kidney malformations). The Consortium has access to the largest clinical cohorts asse ...
Read Project

 29

 FINISHED 
"Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer of the skin associated with the recently discovered, common Merkel cell polyomavirus (MCV). With an incidence of 0.44 per 100,000 MCC is a very rare cancer. Notably, however, although MCC is 40 times less common than malignant melanoma, MCC has a dramatically higher mortality rate than melanoma rendering MCC to ...
Read Project

 11

 FINISHED 

Profiling Responders In Antibody Therapies (PRIAT)

Start date: Nov 1, 2012, End date: Oct 31, 2014,

... ce being pioneers in the field of therapeutic antibody development and (pre-) clinical studies and will tackle both of these challenges:Innovative immunocytokines L19-IL2 and F8-IL10 are developed by Philogen for the treatment of metastatic melanoma and rheumatoid arthritis respectively at multiple clinical centres including Graz and Tübingen.Building on the strong background in proteomics biomark ...
Read Project

 8